Pfizer's Braftovi Approval, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha]
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: Seeking Alpha
SummaryPfizer's Braftovi is approved for colon cancer treatment.Medtronic gets emergency authorization to sell ventilators.Merck's Proventil gets its generic approved.Pfizer Gets FDA Approval for Braftovi in Colon Cancer TreatmentPfizer (PFEannouncedPfizer used the findings from a trial named Beacon for supporting its application. The trial involved the use of Braftovi and Erbitux and demonstrated that the combo improved overall survival to 8.4 months from 5.4 months for patients on chemo alone. The response rate for patients receiving the duo was 20%, in comparison to the response rate of 2% for those who were treated with chemo. The median progression-free survival was 4.2 months for patients on Braftovi and cetuximab combo compared to 1.5 months for patients in the control arm. Braftovi is now the first and only FDA-approved targeted regiment for the condition.Braftovi is also under review for the similar indication in Europe. The application in the region was filed by Pierre Fabre
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $151.00 price target on the stock.MarketBeat
- BioNTech Achieves Minimum Condition in CureVac Exchange OfferGlobeNewswire
- BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time ExpirationGlobeNewswire
- BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Berenberg Bank.MarketBeat
- BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Berenberg Bank.MarketBeat
BNTX
Earnings
- 11/3/25 - Miss
BNTX
Sec Filings
- 12/3/25 - Form 6-K
- 11/28/25 - Form 144
- 11/26/25 - Form 6-K
- BNTX's page on the SEC website